Preferred Label : Osimertinib Mesylate;
NCIt synonyms : 2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-,
Methanesulfonate (1:1); AZD9291 Mesylate;
NCIt definition : The mesylate salt form of osimertinib, a third-generation, orally available, irreversible,
mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential
antineoplastic activity. Upon oral administration, osimertinib covalently binds to
and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired
resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated
signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing
tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays
a key role in tumor cell proliferation and tumor vascularization. As this agent is
selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared
to non-selective EGFR inhibitors which also inhibit wild-type EGFR.;
UNII : RDL94R2A16;
InChIKey : FUKSNUHSJBTCFJ-UHFFFAOYSA-N;
CAS number : 1421373-66-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1421373-66-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Tagrisso; Tagrix;
NCI Metathesaurus CUI : CL1382757;
Origin ID : C170266;
UMLS CUI : C4058810;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_free_acid_or_base_form
- has_target
- is_salt_form_of
